VIP (vasoactive intestinal peptide)
28-residue neuropeptide of the secretin/glucagon family, used in VPAC receptor research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-VIP-5 · ≥99% (see COA) · Lyophilised powder
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA.
VIP (vasoactive intestinal peptide) overview
Vasoactive intestinal peptide is a 28-residue C-terminally amidated neuropeptide. It is supplied as a lyophilised solid for in-vitro laboratory research.
VIP (vasoactive intestinal peptide) research background
Evidence status: Findings summarised here include controlled human trials with mixed or negative results, alongside preclinical research. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
- Agonism at VPAC1 and VPAC2 receptors, with effects including vasodilation, secretion and immune regulation [3].
Research areas & model types
Human clinical research status
- In the TESICO randomised placebo-controlled trial in COVID-19-associated respiratory failure, no significant improvement in recovery was found [4].
Safety observations reported in studies
- Safety outcomes were reported within the TESICO trial setting [4].
Known limitations
- The trial evidence is negative or inconclusive.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed VIP-based immunomodulation [3].
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970. PubMed 5450698 · doi:10.1126/science.169.3951.1217
- Keijzers GB. Aviptadil (Senatek). Curr Opin Investig Drugs. 2001. PubMed 11566015
- Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013. PubMed 22139413 · doi:10.1007/s00726-011-1184-8
- Brown SM, Barkauskas CE, Grund B et al.. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023. PubMed 37348524 · doi:10.1016/S2213-2600(23)00147-9
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Kisspeptin-10
AOD9604
Adamax
CJC-1295 (with DAC)
Browse similar compounds: Neuropeptide research peptides, Endocrine & receptor-signalling research peptides or the full catalogue.